Blog
Published January 24, 2025
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve – particularly in terms of the extent to which CMS will aim for true drug cost reductions vs. generating political capital via nominal “savings” on…
Read Now
Blog
Published January 21, 2025
Trinity recently presented a poster on climate resilience and environmental sustainability at ISPOR EU, titled “Attitudes and Perceptions on Environmental Sustainability Efforts in the Life Sciences Industry: A Cross-Sectional Survey from HEOR and Industry Professionals.” The poster discussed results from a recent survey conducted by our CREST (Climate Resilience and Environmental Sustainability at Trinity) team, which identified perceptions regarding life sciences industry efforts to tackle sustainability, particularly within HEOR, evidence generation and value communication strategy. We also published our new…
Read Now
Blog
Published January 17, 2025
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or JCA.
JCA is an EU initiative intended to improve patient access to health technologies in Europe through a harmonized clinical HTA process. Beginning in January…
Read Now
Blog
Published January 10, 2025
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond oncology and rare pediatric diseases, developers of innovative therapies need to develop strategies targeting patients, providers and payers to overcome these challenges and promote access…
Read Now
Webinars
Available On Demand
Are you ready for the transition and change being forced on the pharmaceutical industry given the unprecedented Customer Relationship Management (CRM) changes announced by Veeva, Salesforce and IQVIA?
The status quo is not an option. Life science companies are being forced to evaluate the implications on their customer strategy and operations as the CRM is one piece of an increasingly integrated ecosystem. The CRM decision will influence commercial and medical data strategy and management, commercial interface architectures, marketing automation…
Watch Now
Blog
Published January 6, 2025
In today’s fast-paced business environment, the ability to harness data effectively can be a game-changer. Companies that can quickly integrate and analyze data from various sources are better positioned to make informed decisions, optimize operations and stay ahead of the competition.
The complexity of managing diverse data sources, ensuring data quality and maintaining consistent performance metrics can be daunting. These challenges are often exacerbated during periods of rapid growth, such as when a company is acquiring new businesses and integrating…
Read Now
Blog
Published December 12, 2024
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics market environment, including the trends below, to determine implications for payers and manufacturers and help them prepare for the year ahead.
Key Trends
Continued Emphasis…
Read Now
Blog
Published December 10, 2024
79% of respondents are predicting an increase in spend in Omnichannel capabilities for Medical Affairs in 2025, according to a recent TGaS survey fielded in September 2024.*
This predicted increase for Medical Omnichannel indicates that there is a real need to find ways to inform, educate and engage HCPs beyond the traditional in-person channel.
What is Medical Omnichannel?
Medical omnichannel is an orchestrated approach to scientific engagement, leveraging analytics and insights to optimize educational content and channels in a customer-centric…
Read Now
Case Studies
The Situation
A mid-size biopharma company had an ambitious inorganic growth strategy but a fragmented data ecosystem, with each brand and function using its own data universe.
There were a variety of data sources, models and integrations. Every brand needed data from different vendors depending on therapeutic area, so data models and integration were implemented for each brand. Maintaining these custom pipelines and ensuring data quality became a resource-intensive exercise as the usage of data grew.
Performance metrics meant different…
Read Now
Scientific Publications
RWD8
Maximizing the Value of Real-World Data in HEOR – a Comparative Assessment of Claims and Emr Sources in Europe
Authors: Diehl M, Saikumar S, Furrer DE, Kulkarni A, Patel N, Hadker N
Abstract:
OBJECTIVES: Heterogeneity in the European RWD landscape, both regionally and across vendors, requires fit-for-purpose dataset selection in HEOR studies. Visibility into RWD elements is crucial for appropriate selection for region-specific, care setting specific use-cases. This research outlines the available data sources and evaluates their advantages and…
Read Now
